![Christopher Aker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Aker
Consejero General en REGULUS THERAPEUTICS INC. .
Fortuna: 23 028 $ al 31/05/2024
Cargos activos de Christopher Aker
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
REGULUS THERAPEUTICS INC. | Consejero General | 20/05/2011 | - |
Secretario Corporativo | 20/05/2011 | - |
Historial de carrera de Christopher Aker
Antiguos cargos conocidos de Christopher Aker.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Director Administrativo | 01/01/2005 | 01/02/2011 |
Consejero General | 01/01/2005 | 01/02/2011 | |
Sugen, Inc.
![]() Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Consejero General | 01/01/2001 | 01/01/2003 |
Formación de Christopher Aker.
University of California, Davis | Undergraduate Degree |
Santa Clara University | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Operativa
General Counsel | 3 |
Corporate Secretary | 1 |
Chief Administrative Officer | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
REGULUS THERAPEUTICS INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Phenomix Corp.
![]() Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Sugen, Inc.
![]() Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Christopher Aker
- Experiencia